6 results  1 of 1 

1 Are you ready to accompany autosomal dominant polycystic kidney disease patients in their treatment journey? Real practice for selecting rapid progressors and treatment with tolvaptan
Yeonsoon Jung, Yun Kyu Oh
Kosin Med J.2023;38(2):87-97.   Published online 2023 June 28     DOI: http://dx.doi.org/10.7180/kmj.23.125
      
2 Vasopressin Receptor Antagonist, Tolvaptan, for Treating Hyponatremia in Patients with Heart Failure
Kyung-Jin Kim
Cardiovasc Prev Pharmacother.2021;3(1):10-14.   Published online 2021 January 31     DOI: http://dx.doi.org/10.36011/cpp.2021.3.e3
      
3 Long-term Tolvaptan Treatment of Autosomal Dominant Polycystic Kidney Disease in Korea
Ha Yeon Kim, Seung Jin Lee, Byung Ki Kim, Minah Kim, Eun Hui Bae, Seong Kwon Ma, Soo Wan Kim
Electrolyte Blood Press.2018;16(2):23-26.   Published online 2019 March 8     DOI: http://dx.doi.org/10.5049/EBP.2018.16.2.23
      
4 Safety and Efficacy of Tolvaptan in Korean Patients with Hyponatremia Caused by the Syndrome of Inappropriate Antidiuretic Hormone
Sang Woong Han, Joo Hark Yi, Kyung Pyo Kang, Ha Yeon Kim, Soo Wan Kim, Hoon Young Choi, Sung-Kyu Ha, Gheun-Ho Kim, Yang Wook Kim, Kyung Hwan Jeong, Sug Kyun Shin, Ho-Jung Kim
J Korean Med Sci.2018;33(15):e112.  Published online 2018 March 20     DOI: http://dx.doi.org/10.3346/jkms.2018.33.e112
      
5 Edematous Hyponatremia Treated with Tolvaptan in a Patient with Amyotrophic Lateral Sclerosis
Gheun-Ho Kim
Electrolyte Blood Press.2017;15(2):37-41.   Published online 2017 December 31     DOI: http://dx.doi.org/10.5049/EBP.2017.15.2.37
      
6 V2 Receptor Antagonist; Tolvaptan
Joo-Hark Yi, Hyun-Jong Shin, Ho-Jung Kim
Electrolyte Blood Press.2011;9(2):50-54.   Published online 2011 December 31     DOI: http://dx.doi.org/10.5049/EBP.2011.9.2.50
      

 1 of 1